# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Raffles Medical Group Ltd |
| Establishment Date | January 1, 1976 |
| Headquarters Location | Singapore, Singapore |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | Raffles Medical Group (RMG) has integrated sustainability into its decision-making processes, focusing on enhancing its technological infrastructure, particularly in cybersecurity and data protection. The Group has implemented a custom-built Laboratory Information System to improve efficiency and testing capacity in its laboratory capabilities. | Raffles Medical Group (RMG) has invested in technologies and sustainable practices, including the launch of a new agent portal by Raffles Health Insurance to enhance operational efficiency and customer experience. Additionally, RMG has expanded its Angiography Suite and commissioned a new Cardiac Catheterisation Laboratory to improve cardiac care services. |
| Product Advantages | RMG offers a comprehensive range of healthcare services, including general and specialized medical services, with a focus on patient-centered care. In 2024, RMG expanded its service offerings by launching new customer solutions through Raffles Health Insurance, including Raffles Critical Illness and Raffles Women's Reproductive Health benefits. | RMG offers a comprehensive range of healthcare services, including specialized medical services through Raffles Hospital and Raffles Health Insurance, which provides innovative products like the Raffles Cancer Guard Rider. The Group has also expanded its product offerings in the maternity and pediatric segments to meet evolving patient needs. |
| Brand Recognition | RMG has established a strong reputation as a trusted healthcare partner, evidenced by its commitment to high-quality patient care and community engagement initiatives. The Group's hospitals and clinics have consistently achieved high customer satisfaction ratings, reflecting its dedication to service excellence. | In 2023, RMG was recognized as the 'Overall Sector Winner' in the Healthcare Services category by The Edge Singapore and received the 'Most Transparent Company Award' in the Healthcare category at the Securities Investors Association of Singapore's 2023 Investors' Choice Award. |
| Reputation Ratings | RMG has obtained ISO 27001 certification for its information security management system, demonstrating its commitment to maintaining high standards in data protection and cybersecurity. Additionally, the Group has received the American Nurses Credentialing Centre (ANCC) Nursing Continuing Professional Development Premier Award, recognizing its excellence in nursing education. | RMG has achieved ISO 27001 certification for its information security management system, demonstrating its commitment to maintaining high standards in data protection and cybersecurity. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | Embodying 'Your Trust, Across Generations,' we strive to enrich our capabilities, guaranteeing that every patient receives the best quality care, fostering lasting relationships across generations. |
| Vision Statement | N/A |
| Core Values | Integrity, Compassion, Excellence |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 751,564.0 | 706,920.0 | 822,916.0 | Thousands | USD |
| Cost of Goods Sold | (61,180.0) | (57,922.0) | (61,112.0) | Thousands | USD |
| Gross Profit | N/A | N/A | N/A | Thousands | USD |
| Operating Expense | (414,450.0) | (367,055.0) | N/A | Thousands | USD |
| Operating Income | 82,494.0 | 115,755.0 | 195,451.0 | Thousands | USD |
| Net Profit | 62,282.0 | 91,090.0 | 143,400.0 | Thousands | USD |
| Income before income taxes | 86,962.0 | 119,439.0 | 191,340.0 | Thousands | USD |
| Income tax expense(benefit) | (24,680.0) | (28,349.0) | (47,940.0) | Thousands | USD |
| Interest Expense | (5,779.0) | (6,078.0) | (6,851.0) | Thousands | USD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 1,530,794.0 | 1,528,230.0 | 1,531,794.0 | Thousands | USD |
| Current Assets | 516,320.0 | 484,697.0 | 494,349.0 | Thousands | USD |
| Non-Current Assets | 1,014,474.0 | 1,043,533.0 | 1,037,445.0 | Thousands | USD |
| Total Liabilities | 465,815.0 | 484,378.0 | 504,044.0 | Thousands | USD |
| Current Liabilities | 381,937.0 | 379,384.0 | 362,990.0 | Thousands | USD |
| Non-Current Liabilities | 83,878.0 | 104,994.0 | 141,054.0 | Thousands | USD |
| Shareholders' Equity | 1,064,979.0 | 1,043,852.0 | 1,027,750.0 | Thousands | USD |
| Retained Earnings | 609,960.0 | 592,293.0 | 572,826.0 | Thousands | USD |
| Total Equity and Liabilities | 1,530,794.0 | 1,528,230.0 | 1,531,794.0 | Thousands | USD |
| Inventories | 10,762.0 | 12,465.0 | 13,098.0 | Thousands | USD |
| Prepaid Expenses | 3,390.0 | 2,658.0 | 4,280.0 | Thousands | USD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 86,254.0 | 189,312.0 | N/A | Thousands | USD |
| Net Cash Flow from Investing | (9,873.0) | (12,409.0) | N/A | Thousands | USD |
| Net Cash Flow from Financing | (76,203.0) | (85,523.0) | N/A | Thousands | USD |
| Net Increase/Decrease in Cash | 178.0 | 91,380.0 | N/A | Thousands | USD |
| Dividends | (44,576.0) | (70,683.0) | (70,473.0) | Thousands | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 108.14% | 108.19% | 107.43% | Thousands | USD |
| Operating Margin | 10.98% | 16.37% | 23.75% | Thousands | USD |
| Net Profit Margin | 8.29% | 12.89% | 17.43% | Thousands | USD |
| Current Ratio | 135.18% | 127.76% | 136.19% | Thousands | USD |
| Quick Ratio | 131.48% | 123.77% | 131.40% | Thousands | USD |
| Interest Coverage | 1427.48% | 1904.49% | 2852.88% | Thousands | USD |
| Asset Turnover | 49.14% | 46.20% | N/A | Thousands | USD |
| Debt-to-Equity | 43.74% | 46.40% | 49.04% | Thousands | USD |
| Return on Equity | 5.91% | 8.79% | N/A | Thousands | USD |
| Return on Assets | 4.07% | 5.95% | N/A | Thousands | USD |
| Effective Tax Rate | 28.38% | 23.74% | 25.05% | Thousands | USD |
| Dividend Payout Ratio | 71.57% | 77.60% | 49.14% | Thousands | USD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Healthcare services: $295,050, Hospital services: $345,652, Insurance services: $178,000, Investment holdings: $44,894 | Healthcare services: $295,050, Hospital services: $330,589, Insurance services: $139,681, Investment holdings: $45,223 | N/A |
| Revenue by Geographic Region | Singapore: $669,145, Greater China: $65,302, Rest of Asia: $17,117 | Singapore: $631,108, Greater China: $59,324, Rest of Asia: $16,488 | N/A |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | Revenue decreased from 822,916 in 2022 to 706,920 in 2023, representing a decline of approximately 14.14%. However, there was a slight recovery in 2024 with revenue increasing to 751,564, marking a growth of about 6.31% from 2023. The gross margin remained relatively stable, with a slight increase from 107.43% in 2022 to 108.19% in 2023, and a marginal decrease to 108.14% in 2024. Revenue by product shows that hospital services grew from 330,589 in 2023 to 345,652 in 2024, while insurance services increased from 139,681 to 178,000 in the same period. Geographic revenue distribution indicates a strong performance in Singapore, which grew from 631,108 in 2023 to 669,145 in 2024, while Greater China and Rest of Asia also showed modest growth. |
| Operating Efficiency | Operating margin showed a declining trend from 23.75% in 2022 to 16.37% in 2023, and further down to 10.98% in 2024, indicating a significant deterioration in operating efficiency. Operating income decreased from 195,451 in 2022 to 115,755 in 2023, and further to 82,494 in 2024, reflecting a concerning relationship between operating income and revenue. The increase in operating expenses from 367,055 in 2023 to 414,450 in 2024 suggests challenges in cost management, which may be impacting overall profitability. |
| External & One-Off Impact | The effective tax rate increased from 23.74% in 2023 to 28.38% in 2024, which could negatively impact net profitability. Non-recurring items were not explicitly mentioned, but the overall decline in net profit from 143,400 in 2022 to 62,282 in 2024 suggests potential external pressures or unusual patterns affecting profitability. Factors such as market conditions or regulatory changes in the healthcare sector may be influencing these results. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, the company's total assets slightly increased to $1,530,794, while total liabilities decreased to $465,815, indicating improved balance sheet strength. The equity position strengthened with shareholders' equity rising to $1,064,979, reflecting a solid asset base. The current ratio improved to 135.18%, suggesting enhanced liquidity and a strong capital structure. | In 2023, total assets were $1,528,230, with total liabilities at $484,378, indicating a reduction in leverage. Shareholders' equity was $1,043,852, showing a positive trend in equity position. The current ratio was 127.76%, which indicates a stable liquidity position, although slightly lower than in 2024. |
| Profitability and earnings quality | The revenue for 2024 reached $751,564, showing growth from $706,920 in 2023. However, net profit decreased to $62,282, resulting in a net profit margin of 8.29%, down from 12.89% in 2023. The return on equity (ROE) was 5.91%, indicating a decline in profitability compared to 8.79% in 2023, suggesting challenges in maintaining earnings quality. | In 2023, the company reported revenue of $706,920 and a net profit of $91,090, resulting in a net profit margin of 12.89%. The operating income was $115,755, reflecting a healthy operating margin of 16.37%. The ROE was 8.79%, indicating strong profitability and earnings sustainability during this period. |
| Operational efficiency | Operational efficiency in 2024 showed a decline, with an operating margin of 10.98%, down from 16.37% in 2023. The asset turnover ratio improved to 49.14%, indicating better asset utilization. However, net cash from operations significantly decreased to $86,254 from $189,312 in 2023, raising concerns about working capital management. | In 2023, the operating margin was 16.37%, reflecting effective cost management. The asset turnover ratio was 46.20%, indicating reasonable asset utilization. The net cash from operations was robust at $189,312, suggesting strong operational performance and effective working capital management. |
| Financial risk identification and early warning | In 2024, the debt to equity ratio improved to 43.74%, indicating better debt management. The interest coverage ratio remained high at 1427.48%, suggesting low financial risk. However, the effective tax rate increased to 28.38%, which could impact future profitability. Liquidity ratios remained strong, indicating a solid solvency position. | The debt to equity ratio in 2023 was 46.40%, showing a moderate level of financial risk. The interest coverage ratio was 1904.49%, indicating strong ability to cover interest expenses. The effective tax rate was lower at 23.74%, which positively impacted net income, but the overall financial risk was still present due to the leverage levels. |
| Future financial performance projection | Looking ahead, the company is expected to focus on investment activities, particularly in healthcare and hospital services, which are showing revenue growth. However, the decline in net cash from operations raises concerns about cash flow sustainability. The dividend policy appears to be conservative, with dividends decreasing to $44,576, indicating a focus on retaining earnings for growth. | In 2023, the company was positioned for growth with a strong revenue base and effective operational strategies. The cash flow from operations was robust, allowing for potential reinvestment in business development. The dividend payout was higher at $70,683, reflecting confidence in future earnings, although the company needed to manage its cash flow carefully to sustain this growth. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | The company primarily operates in the healthcare sector, generating revenue through multiple segments: healthcare services (medical clinics, pharmaceutical trading, management and consultancy services), hospital services (specialized medical services and hospital operations), investment holdings (leasing investment properties), and insurance services (health insurance products). Revenue is recognized upon the completion of services or delivery of goods, with significant income derived from contracts with customers and rental income from investment properties. | The company operates through four reportable segments: Healthcare services, Hospital services, Investment holdings, and Insurance services. It generates revenue primarily from the provision of medical services, inpatient services, and trading in pharmaceutical and nutraceutical products. Revenue is recognized when services are rendered or goods are delivered. The healthcare services segment also includes management and consultancy services, while the investment holdings segment generates revenue from leasing investment properties. |
| Market Position | The company is a market leader in the healthcare industry, particularly in Singapore, where it has a significant presence. It faces keen competition from both established players and new entrants, necessitating continuous innovation and improvement to maintain its competitive edge. The company recognizes the need to expand its capabilities as it grows beyond Singapore, adapting to diverse regulatory and cultural environments. Specific market share data is not provided, but the company aims to strengthen its position and retain market share amidst increasing competition. | The company is positioned as a market leader in the healthcare sector, with a significant presence in Singapore and expansion into other Asian markets. It serves over 2.8 million patients and 7,000 corporate clients. The company has a strong reputation for clinical quality and patient safety, which are highly valued by its stakeholders. Specific market share data is not provided, but the company emphasizes its competitive edge through high-quality service delivery and patient satisfaction. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | The Group faces market risks from keen competition in the healthcare industry, including threats from new entrants and consolidation of smaller practices. To maintain its competitive edge, the Group recognizes the need to enhance its capabilities and adapt to diverse regulatory environments as it expands beyond Singapore. | The Group is exposed to currency risk on borrowings and inter-company balances denominated in foreign currencies, which could impact profitability. Additionally, market risk includes fluctuations in interest rates that affect interest-earning financial assets and liabilities. |
| Operational Risks | Operational risks include potential business disruptions due to external factors beyond the Group's control, despite its demonstrated resilience during recent pandemics. The Group relies heavily on IT systems for operations, making cybersecurity a critical concern, which is addressed through continuous training and external security assessments. | Operational risks include disruptions due to external factors such as pandemics, which can affect service delivery and operational continuity. The Group has implemented a robust risk management framework to enhance operational resilience and ensure compliance with health and safety standards. |
| Financial Risks | The Group is exposed to various financial risks, including credit, liquidity, foreign currency, and interest rate risks. It actively manages these risks through policies that ensure adequate liquidity and monitoring of financial instruments to mitigate adverse impacts on its financial performance. | The Group faces financial risks including credit, liquidity, foreign currency, and interest rate risks. To mitigate liquidity risk, the Group maintains sufficient cash reserves and undrawn credit facilities to meet its obligations under both normal and stressed conditions. |
| Compliance Risks | The Group operates in a highly regulated environment, requiring adherence to various licensing and governmental approvals. To mitigate compliance risks, the Group closely monitors regulatory developments and engages with authorities to ensure compliance with evolving standards. | The Group operates in a highly regulated environment, requiring adherence to various licensing and governmental approvals. To minimize compliance risks, the Group actively monitors regulatory developments and engages with authorities to ensure alignment with changing regulations. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Dr Loo Choon Yong | Executive Chairman and Non-Independent Director | £7,333,190,000 |
| Mr Tan Soo Nan | Executive and Non-Independent Director | £516,579,000 |
| Dr Sarah Lu Qinghui | Executive and Non-Independent Director | £413,893,000 |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | The Group has adopted an Enterprise Risk Management (ERM) framework to enhance its risk management capabilities. The ERM framework provides a holistic overview of the Group's risk profile by identifying key risks, control measures, risk tolerance, risk ownership and assurance on residual risk, and is reviewed by the ARC and approved by the Board annually. The risk assessment exercise includes identifying and assessing key risk areas such as financial, operational, compliance, information technology, and climate-related risks based on feedback from internal and external auditors. | The Group has adopted an entity-wide risk assessment framework to enhance its risk management capabilities. This framework provides a holistic overview of the Group's risk profile by identifying key risks, control measures, risk tolerance, risk ownership, and assurance on residual risk. The framework is reviewed by the Audit & Risk Committee (ARC) and approved by the Board annually. The Group conducts regular Enterprise Risk Assessment exercises at least once a year to keep up to date on its risks, including climate-related risks. |
| Control activities | The Group has implemented various control measures, including compliance frameworks, codes of conduct, and operational procedures. The ARC oversees the Group's procedures for detecting fraud and whistle-blowing, ensuring arrangements are in place for staff to raise concerns confidentially. The internal audit function operates within a framework approved by the ARC and adopts a risk-based audit methodology to align its activities with key risks across the Group. | The Group has established risk management policies to identify and analyze risks, set appropriate risk limits and controls, and monitor risks and adherence to limits. Specific control measures include a Code of Business Conduct, a whistleblowing policy, and training on data security, anti-bribery, and anti-corruption. The Group also has a Block Leave Policy for employees in key functions to ensure checks and balances. |
| Monitoring mechanisms | The Audit & Risk Committee (ARC) monitors the effectiveness of internal controls and risk management. The internal audit function reports directly to the ARC, providing independent assurance on the adequacy and effectiveness of the ERM framework and internal controls. The Management Risk Committee (MRC) reviews and implements risk management and internal controls, meeting quarterly to discuss escalated risk events and assess the adequacy of existing frameworks. | The Audit & Risk Committee oversees the Group's risk management and internal controls, reviewing the adequacy and effectiveness of these systems annually. Internal Audit provides independent assurance on the adequacy and effectiveness of the risk management framework and internal controls, reporting directly to the ARC. The Management Risk Committee (MRC) meets quarterly to review and assess the adequacy and effectiveness of the existing Risk Management Framework and Internal Controls. |
| Identified material weaknesses or deficiencies | While no specific material weaknesses were identified, the ARC reviews reports from internal auditors regarding any material non-compliance or lapses in internal controls, along with recommendations for improvement. | N/A |
| Effectiveness | The Board, with the concurrence of the ARC, is of the opinion that the Group has adequate and effective risk management systems and internal controls in place to mitigate critical and significant risks. The ARC is satisfied that the internal audit function is effective, adequately resourced, and independent, and that the Group's internal control and risk management systems are adequate and effective. | The Board, with the concurrence of the ARC, is of the opinion that the Group has adequate and effective risk management systems and internal controls in place to mitigate critical and significant risks. The ARC is satisfied that the internal audit function is effective, adequately resourced, and independent, and that the Group's internal control and risk management systems are adequate and effective. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | On 18 January 2024, RJC Ltd, a subsidiary of the Company, completed the acquisition of the remaining 49% which it does not already hold in the equity interest of RSM Ltd, Japan, making RSM a wholly owned subsidiary. Additionally, on 25 April 2024, the Group acquired an additional 7.5% equity interest in Raffles Japanese Clinic Pte Ltd (RJC), increasing its ownership from 80% to 87.5%. The carrying amount of RJC's net assets at the time of acquisition was $16,482,000. | In 2023, RJC Ltd, a subsidiary of the Company, completed the acquisition of the remaining 49% equity interest in RSM Ltd, Japan, for a total cash consideration of JPY40,089,000 ($367,000). This acquisition makes RSM Ltd a wholly owned subsidiary and is part of the Group's strategy to expand its operations in Japan. |
| New technologies | In 2024, Raffles Hospital enhanced its laboratory capabilities by implementing a custom-built Laboratory Information System to improve efficiency and testing capacity. Additionally, the Group has invested in upgrading its IT systems to keep pace with technological advancements, including obtaining ISO 27001 certification for its information security management system. | The Group has invested in a new Cardiology PACS platform that allows cardiologists to view and report cardiac tests remotely and efficiently. Additionally, Raffles Health Insurance launched new products, including the Raffles Cancer Guard Rider, which offers protection for patients using treatments not included in the Ministry of Health's Cancer Drug List. The Group is also focused on digitalising solutions to enhance operational efficiency. |
| Organisational Restructuring | The Group has implemented various employee well-being and welfare programs aimed at fostering a positive workplace culture, enhancing employee retention, and supporting overall organizational success. In 2024, the Human Capital team organized the Employee Well-being Week, which included health screenings and educational sessions. The Group also increased its investment in staff training, resulting in a total of 66,656 training hours completed by employees. | The Group has implemented various talent management initiatives, including a new Workforce Skills Qualification (WSQ)-certified course for supervisors and managers to improve staff morale and productivity. The Group also offers continuous education programs for healthcare talent and has established a robust succession planning process to develop management capabilities. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | The Group faces economic challenges related to rising costs of energy and water, which are anticipated to continue increasing. This trend is likely to impact operational expenses and sustainability efforts. Additionally, the Group is exposed to financial risks including credit, liquidity, foreign currency, and interest rate risks, which require proactive management to mitigate potential adverse effects on financial performance. | The slower economic growth in Singapore, China, and other ASEAN countries is a concern, compounded by growing trade barriers and various geopolitical tensions. These factors necessitate a cautious approach, although there is confidence that as economies recover and geopolitical tensions diminish, growth will accelerate. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | The Group experiences keen competition from both established players and new entrants in the healthcare industry. The consolidation of smaller practices can create new competitors of significant size and scale, challenging the Group's market position. As the Group expands beyond Singapore, it must develop expertise to navigate diverse regulatory and cultural environments while enhancing its organizational capabilities to address competitive threats and maintain its market share. | The Group faces keen competition from both established players and new entrants in the healthcare industry. The consolidation of smaller practices poses a threat by creating new competitors of significant size and scale. Additionally, as the Group expands beyond Singapore, it must develop expertise to navigate different regulatory and cultural environments, which presents challenges in maintaining its competitive edge. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | In 2023, Raffles Medical Group Ltd focused on enhancing operational efficiency through digital solutions, including the launch of a new agent portal for Raffles Health Insurance. The company also invested in expanding its healthcare capabilities, particularly in specialty services and technology, such as a new Cardiology PACS platform for remote cardiac test reporting. The total R&D investment for FY2023 was S$144.5 million, reflecting a commitment to advancing healthcare delivery and technology. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | In 2024, Raffles Health Insurance launched several new customer solutions, including Raffles Critical Illness for the Personal Lines market and the Raffles Women's Reproductive Health benefit for the Group Employee Benefits market. Additionally, Raffles Health developed and launched an oral skincare supplement, backed by clinical research, designed to combat skin aging and provide protection against sun damage. These initiatives reflect the company's commitment to continuously introducing differentiated products that cater to evolving health insurance needs and consumer preferences. | Raffles Medical Group Ltd launched several new products in FY2023, including the Raffles Cancer Guard Rider, which provides additional cancer coverage with unique features like traditional Chinese medicine and psychiatric counseling. Additionally, the company introduced its first Digital Term Life product, available exclusively through a digital portal. These innovations are designed to meet evolving market demands and enhance customer experience, positioning the company competitively in the healthcare market. |
